Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.03 USD
Change Today -0.0015 / -5.08%
Volume 128.2K
RGIN On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

regenicin inc (RGIN) Snapshot

Open
$0.03
Previous Close
$0.03
Day High
$0.03
Day Low
$0.03
52 Week High
02/20/15 - $0.04
52 Week Low
10/9/14 - $0.0019
Market Cap
4.0M
Average Volume 10 Days
120.3K
EPS TTM
$0.01
Shares Outstanding
143.4M
EX-Date
--
P/E TM
2.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENICIN INC (RGIN)

Related News

No related news articles were found.

regenicin inc (RGIN) Related Businessweek News

No Related Businessweek News Found

regenicin inc (RGIN) Details

Regenicin, Inc., a biotechnology company, develops regenerative cell therapies to restore the health of damaged tissues and organs in the United States. The company intends to develop and commercialize a technology of tissue-engineered skin substitutes to restore the healthy human skin qualities for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its product includes TempaDerm, a cultured skin substitute for use in the treatment of chronic skin wounds comprising diabetic ulcers, decubitus ulcers, and venous stasis ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is headquartered in Little Falls, New Jersey.

3 Employees
Last Reported Date: 01/13/15
Founded in 2007

regenicin inc (RGIN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $125.0K
Chief Financial Officer and Director
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: --
Chief Science Officer
Total Annual Compensation: $125.0K
Compensation as of Fiscal Year 2014.

regenicin inc (RGIN) Key Developments

Regenicin, Inc. announced delayed 10-Q filing

On 02/17/2015, Regenicin, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Regenicin, Inc. announced delayed annual 10-K filing

On 12/29/2014, Regenicin, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Regenicin, Inc. announced delayed 10-Q filing

On 08/12/2014, Regenicin, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGIN:US $0.03 USD -0.0015

RGIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGIN.
View Industry Companies
 

Industry Analysis

RGIN

Industry Average

Valuation RGIN Industry Range
Price/Earnings 1.3x
Price/Sales -- Not Meaningful
Price/Book 5.8x
Price/Cash Flow 0.9x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENICIN INC, please visit www.regenicin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.